Cervical CancerNCT04374760
Increasing Cervical Cancer Screening Uptake Among Emergency Department Patients
A study testing SMS-intervention in people with Cervical Cancer, run by University of Rochester at 2 sites in United States.
Trial summary
Invasive cervical cancer is preventable with adequate screening but screening rates are considerably below national goals. Emergency departments care for a disproportionate number of women who are not up to date with recommended cervical cancer screening. Read more about this study
- Who is it for?
- Ages 21 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cervical Cancer
- What is being tested?
- SMS-intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,116 participants
- Where
- 2 sitesUnited States
- Study dates
- 3 Dec 2020to 31 Jan 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- female
- age 21 - 65 years
- demonstrating decisional capacity to consent to participate
Who cannot join
- past hysterectomy with cervical removal
- the absence of a cervix (i.e. in patient that is a transwoman
- known infection with HIV (as screening recommendations for women with HIV differ from the general population)
- inability to consent (e.g., lacking decisional capacity, intoxicated, or in distress)
- non-English/Spanish/American Sign Language (ASL) speaking (Spanish and ASL interpreter services are available 24/7 in our system and will be paid for through grant funds)
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Nicolas Noyes Community Hospital
Dansville, New York, 14437
Strong Memorial Hospital Emergency Department
Rochester, New York, 14642
About this study
Invasive cervical cancer is preventable with adequate screening but screening rates are considerably below national goals. Emergency departments care for a disproportionate number of women who are not up to date with recommended cervical cancer screening. This study will evaluate the effectiveness of a mobile technology based behavioral intervention (using text messaging prompts) to increase cervical cancer screening uptake among emergency department patients.
Read the detailed description
Cervical cancer (CC) is preventable. Screening for CC aims to identify treatable lesions prior to the development of invasive CC which, without screening, is often first detected at a stage when comfort care is all that can be offered. Still, only 80% of U.S. women age 21 - 65 report adherence to U.S. Preventive Services Task Force (USPSTF) CC screening recommendations. This rate is considerably below the Healthy People 2020 target of 93%8. Lower rates of screening have been particularly pronounced among racial and ethnic minorities and patients with lower education levels. The group most likely to be non-adherent with screening guidelines is women who use the emergency department (ED) for their usual source of care. The ED setting, therefore, is optimal for the deployment of an intervention to promote CC screening. Although designed to address acute illnesses and injuries, the ED is an effective environment to advance preventive health. Numerous preventive health interventions have been successfully deployed in the ED including smoking cessation, HIV testing, and depression screening. Interventions delivered in the ED often suffer from lack of follow up and hence low adherence. Novel approaches are needed to reinforce health messages delivered in the acute context of the ED. Short Message Service (SMS) on mobile phones, also known as text messaging, is a low-cost, scalable, and effective means of delivering health behavior interventions. According to the Pew Research Center, the vast majority of Americans - 95% - own a cell phone, and an estimated 98% of all cell phones have texting capabilities. Evidence-based SMS interventions for health behavior include smoking cessation,primary care attendance, breast cancer screening, and sun safety, among others. However, minimal research has been conducted applying SMS interventions to CC screening and no prior research, apart from our pilot work, has targeted a CC prevention intervention by leveraging the universal healthcare access setting of the ED. In 2018-19 the investigators conducted a randomized clinical trial pilot (ClinicalTrials.gov #NCT03483610; NIH Grant ID: UL1TR002001) among ED patients non-adherent with USPSTF recommendations comparing an SMS intervention group to a referral-only control group to improve CC screening uptake at follow-up. The intervention consisted of a series of text messages, grounded in behavioral change theory, aimed at generating intention to get screened. The results of this pilot: (A) demonstrated the feasibility of our approach, (B) showed preliminary evidence of efficacy, and (C) provided an effect size estimate. Our overarching goal is to develop a low-cost, scalable SMS intervention that increases CC screening uptake among ED patients and can be deployed in heterogenous ED settings. The proposed randomized controlled trial will test the efficacy of this intervention. Step 1 of our approach is to identify whether the participant is adherent with screening guidelines. Step 2 is to randomize non-adherent participants to one of the two treatment conditions: (1) referral only (control) or, (2) referral and an SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened. To limit costs and increase the scalability of the intervention, determination of adherence with screening guidelines via a self-administered questionnaire on a tablet computer will be evaluated. A total of 1,460 non-adherent women, age 21-65, will be recruited from a high-volume urban ED and a low-volume rural ED, randomized among study conditions, and followed-up at 150 days to assess interval CC screening uptake.
Aim 1: Compare CC screening uptake between SMS intervention and control groups. Hypothesis 1: Uptake of CC screening in the SMS intervention group will be greater than in the control group at 150-day follow-up.This aim will determine the efficacy of the intervention.
Aim 2: Compare the impact of in-person (using research staff) versus self-administered (using a tablet) determination of CC screening adherence on the efficacy of the intervention.
Hypothesis 2: The method of determining adherence will not impact the efficacy of the intervention. This aim will evaluate an approach to limit cost and increase the scalability of intervention implementation. Aim 3: Identify mediators and explore moderators of intervention effects on CC screening uptake at follow-up.
Hypothesis 3: Uptake in the intervention group will be mediated by theory-posited proximal predictors. This aim will elucidate the mechanism of behavioral change resulting from the intervention and identify differential effects among study sub-groups.
This project leverages the universal access setting of the ED to target women most at risk for non-adherence with CC screening guidelines. A low-cost, scalable intervention that increases CC screening uptake in this population would decrease CC incidence and save lives. Our next step would be a multi-site effectiveness trial using the NCI Community Oncology Research Program (NCORP) Network.
- Conditions
- Cervical Cancer
- Being tested
- SMS-intervention
- Keywords
- screening adherence
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SMS-interventionBehavioural
SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.
| Study group | Role | What they receive |
|---|---|---|
| in-person control | No intervention | Usual care, initial screening measures conducted in-person in the Emergency Department. |
| Self-Administered Control | No intervention | Usual care, initial screening measures conducted on their own via an iPad. |
| In-person Treatment | Experimental | Treatment group (receives text messages), initial screening measures conducted in-person in the Emergency Department. Receives: Behavioral: SMS-intervention |
| Self-Administered Treatment | Experimental | Treatment group (receives text messages), initial screening measures conducted on their own via an iPad. Receives: Behavioral: SMS-intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of screening for cervical cancer
The investigators will perform logistic regression comparing the treatment and control conditions on CC screening uptake (defined as either receiving CC screening or scheduling CC screening) at followup. The use of logistic regression, rather than a χ² test of independence, allows for (a) the inclusion of potential relevant covariates in the unlikely case of baseline group differences and (b) the examination of moderation/interaction in later primary analyses. Given the sample size of 1,460 non-adherent participants, the investigators will have power of 0.80 to observe an improvement in CC screening uptake of 19% as observed in the pilot study (i.e., 36% vs 43%). This is a conservative estimate of the anticipated effect size given the increased intervention intensity, incorporation of additional theoretically informed messages to participants, and the above-mentioned failures in randomization that occurred with our small pilot sample.
Measured: 150 days
Secondary outcomes (1)
Self-administered vs in-person baseline technique
The investigators will perform a 2 X 2 χ² of individuals in the treatment condition (n = 730) examining differences in CC uptake across method of determination. These data will be analyzed as a non-inferiority trial, such that we will have power greater than 0.80 to show that the Self-Administered method for determining adherence does not negatively impact intervention efficacy (up to a 9.1% difference). The investigators will also perform logistic regression on the complete non-adherent sample using intervention condition, method for determining adherence, and the interaction between condition and method to predict CC screening uptake, with a null finding for the interaction (meaning method does not impact the effect of the intervention) supporting the case for non-inferiority of the Self-Administered method.
Measured: 150 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2020
- Study start3 Dec 2020
- Primary completion31 Jul 2023
- Study completion31 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical CancerStudies of the same condition, open and under way.
- More trials run by University of RochesterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled clinical trial with a prospectively collected convenience sample of 1,460 women nonadherent with CC screening guidelines. Women aged 21-65 will be recruited from a high-volume urban ED and a low-volume rural ED, assigned to study conditions, and followed-up at 150 days to assess interval uptake of CC screening (primary outcome). Electronic Health Record (EHR) review will be conducted to assess screening results and subsequent clinical endpoints. A two-step randomization process will be used to achieve a 2 x 2 factorial design.
- Masking
- None (open label)
- Enrolment
- 1,116 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Rochester
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Principal investigator, David Adler, University of Rochester
- Investigators
- David Adler, MD, Principal investigator, University of Rochester
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04374760
- Sponsor's protocol ID
- STUDY00004765
- Other IDs
- 1R01CA246626
- Status last verified
- Apr 2024
- First submitted
- 30 Apr 2020
- Last updated
- 24 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Increasing Cervical Cancer Screening Uptake Among Emergency Department Patients
- ClinicalTrials.gov ID
- NCT04374760
- Acronym / sponsor ID
- STUDY00004765
- Conditions
- Cervical Cancer
- Keywords
- screening adherence
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,116 participants (actual)
- Lead sponsor
- University of RochesterUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 3 Dec 2020 (actual)
- Primary completion
- 31 Jul 2023 (actual)
- Study completion
- 31 Jan 2024 (actual)
- First posted
- 5 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Invasive cervical cancer is preventable with adequate screening but screening rates are considerably below national goals. Emergency departments care for a disproportionate number of women who are not up to date with recommended cervical cancer screening. This study will evaluate the effectiveness of a mobile technology based behavioral intervention (using text messaging prompts) to increase cervical cancer screening uptake among emergency department patients.
Detailed description
Cervical cancer (CC) is preventable. Screening for CC aims to identify treatable lesions prior to the development of invasive CC which, without screening, is often first detected at a stage when comfort care is all that can be offered. Still, only 80% of U.S. women age 21 - 65 report adherence to U.S. Preventive Services Task Force (USPSTF) CC screening recommendations. This rate is considerably below the Healthy People 2020 target of 93%8. Lower rates of screening have been particularly pronounced among racial and ethnic minorities and patients with lower education levels. The group most likely to be non-adherent with screening guidelines is women who use the emergency department (ED) for their usual source of care. The ED setting, therefore, is optimal for the deployment of an intervention to promote CC screening. Although designed to address acute illnesses and injuries, the ED is an effective environment to advance preventive health. Numerous preventive health interventions have been successfully deployed in the ED including smoking cessation, HIV testing, and depression screening. Interventions delivered in the ED often suffer from lack of follow up and hence low adherence. Novel approaches are needed to reinforce health messages delivered in the acute context of the ED. Short Message Service (SMS) on mobile phones, also known as text messaging, is a low-cost, scalable, and effective means of delivering health behavior interventions. According to the Pew Research Center, the vast majority of Americans - 95% - own a cell phone, and an estimated 98% of all cell phones have texting capabilities. Evidence-based SMS interventions for health behavior include smoking cessation,primary care attendance, breast cancer screening, and sun safety, among others. However, minimal research has been conducted applying SMS interventions to CC screening and no prior research, apart from our pilot work, has targeted a CC prevention intervention by leveraging the universal healthcare access setting of the ED. In 2018-19 the investigators conducted a randomized clinical trial pilot (ClinicalTrials.gov #NCT03483610; NIH Grant ID: UL1TR002001) among ED patients non-adherent with USPSTF recommendations comparing an SMS intervention group to a referral-only control group to improve CC screening uptake at follow-up. The intervention consisted of a series of text messages, grounded in behavioral change theory, aimed at generating intention to get screened. The results of this pilot: (A) demonstrated the feasibility of our approach, (B) showed preliminary evidence of efficacy, and (C) provided an effect size estimate. Our overarching goal is to develop a low-cost, scalable SMS intervention that increases CC screening uptake among ED patients and can be deployed in heterogenous ED settings. The proposed randomized controlled trial will test the efficacy of this intervention. Step 1 of our approach is to identify whether the participant is adherent with screening guidelines. Step 2 is to randomize non-adherent participants to one of the two treatment conditions: (1) referral only (control) or, (2) referral and an SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened. To limit costs and increase the scalability of the intervention, determination of adherence with screening guidelines via a self-administered questionnaire on a tablet computer will be evaluated. A total of 1,460 non-adherent women, age 21-65, will be recruited from a high-volume urban ED and a low-volume rural ED, randomized among study conditions, and followed-up at 150 days to assess interval CC screening uptake.
Aim 1: Compare CC screening uptake between SMS intervention and control groups. Hypothesis 1: Uptake of CC screening in the SMS intervention group will be greater than in the control group at 150-day follow-up.This aim will determine the efficacy of the intervention.
Aim 2: Compare the impact of in-person (using research staff) versus self-administered (using a tablet) determination of CC screening adherence on the efficacy of the intervention.
Hypothesis 2: The method of determining adherence will not impact the efficacy of the intervention. This aim will evaluate an approach to limit cost and increase the scalability of intervention implementation. Aim 3: Identify mediators and explore moderators of intervention effects on CC screening uptake at follow-up.
Hypothesis 3: Uptake in the intervention group will be mediated by theory-posited proximal predictors. This aim will elucidate the mechanism of behavioral change resulting from the intervention and identify differential effects among study sub-groups.
This project leverages the universal access setting of the ED to target women most at risk for non-adherence with CC screening guidelines. A low-cost, scalable intervention that increases CC screening uptake in this population would decrease CC incidence and save lives. Our next step would be a multi-site effectiveness trial using the NCI Community Oncology Research Program (NCORP) Network.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- Randomized controlled clinical trial with a prospectively collected convenience sample of 1,460 women nonadherent with CC screening guidelines. Women aged 21-65 will be recruited from a high-volume urban ED and a low-volume rural ED, assigned to study conditions, and followed-up at 150 days to assess interval uptake of CC screening (primary outcome). Electronic Health Record (EHR) review will be conducted to assess screening results and subsequent clinical endpoints. A two-step randomization process will be used to achieve a 2 x 2 factorial design.
| Arm | Type | Receives |
|---|---|---|
| in-person control | No intervention | –Usual care, initial screening measures conducted in-person in the Emergency Department. |
| Self-Administered Control | No intervention | –Usual care, initial screening measures conducted on their own via an iPad. |
| In-person Treatment | Experimental | Behavioral: SMS-interventionTreatment group (receives text messages), initial screening measures conducted in-person in the Emergency Department. |
| Self-Administered Treatment | Experimental | Behavioral: SMS-interventionTreatment group (receives text messages), initial screening measures conducted on their own via an iPad. |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- female
- age 21 - 65 years
- demonstrating decisional capacity to consent to participate
Key exclusion criteria (5 listed)
- past hysterectomy with cervical removal
- the absence of a cervix (i.e. in patient that is a transwoman
- known infection with HIV (as screening recommendations for women with HIV differ from the general population)
- inability to consent (e.g., lacking decisional capacity, intoxicated, or in distress)
- non-English/Spanish/American Sign Language (ASL) speaking (Spanish and ASL interpreter services are available 24/7 in our system and will be paid for through grant funds)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SMS-interventionSMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened. | Behavioural | In-person Treatment, Self-Administered Treatment |
Primary outcome
Rate of screening for cervical cancer
Time frame: 150 days
The investigators will perform logistic regression comparing the treatment and control conditions on CC screening uptake (defined as either receiving CC screening or scheduling CC screening) at followup. The use of logistic regression, rather than a χ² test of independence, allows for (a) the inclusion of potential relevant covariates in the unlikely case of baseline group differences and (b) the examination of moderation/interaction in later primary analyses. Given the sample size of 1,460 non-adherent participants, the investigators will have power of 0.80 to observe an improvement in CC screening uptake of 19% as observed in the pilot study (i.e., 36% vs 43%). This is a conservative estimate of the anticipated effect size given the increased intervention intensity, incorporation of additional theoretically informed messages to participants, and the above-mentioned failures in randomization that occurred with our small pilot sample.
1 secondary outcome
Self-administered vs in-person baseline technique
Time frame: 150 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2024.
- Individual participant dataSharing planned: No
Related trials for Cervical Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Adler, MD principal investigator
University of Rochester
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SMS-intervention in people with Cervical Cancer, run by University of Rochester at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of screening for cervical cancer (time frame: 150 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2024.